Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974847 | 1.00 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL8037342 | 1.00 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL23527440 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL4535082 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL23527439 | 0.98 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL5712566 | 0.85 | SLC6A4 (0.48) | SLC6A4 | |
| SCHEMBL5652929 | 0.85 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL16692504 | 0.85 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL3489363 | 0.82 | GBA1 (0.48) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL3446697 | 0.82 | GBA1 (0.48) | OPRM1OPRD1OPRK1OPRL1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458463-B2 | Method for treatment of diabetes by a small molecule inhibitor for GRK5 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-10-04 | — | — | US | claimed |
| WO-2015022437-A1 | INDOLINONE DERIVATIVES AS GRK5 MODULATORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-02-19 | — | — | WO | claimed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3215510-B1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2023-06-07 | — | — | EP | disclosed |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2022-08-02 | — | — | US | disclosed |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2021-06-10 | — | — | US | disclosed |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2019156929-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | eXIthera Pharmaceuticals Inc. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2019-07-18 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
| EP-3215510-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| CN-1039997-C | Cyanoquanidines as k-channel blockers | PHAMACIA AND UPJOHN CO (US) | 1998-09-30 | — | — | CN | disclosed |
| EP-0655057-B1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | UPJOHN CO (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5567722-A | DIURETICS | THE UPJOHN COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| EP-0600507-B1 | 3-Azabicyclo(3.1.0.)hexane-2-one derivatives and Herbicidal Compositions Containing them as Herbicidally Active Ingredients | MITSUI TOATSU CHEMICALS (JP) | 1996-03-06 | — | — | EP | disclosed |
| CN-1090575-A | K-channel blocker dicyanodiamide class | UPJOHN CO (US) | 1994-08-10 | — | — | CN | disclosed |
| WO-1994004500-A1 | CYANOGUANIDINES AS POTASSIUM CHANNEL BLOCKERS | THE UPJOHN COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | OPRM1 872/4885OPRD1 1216/4885OPRK1 806/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | OPRM1 470/4885OPRD1 307/4885OPRK1 184/4885 |
| US-20190216813-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | OPRM1 805/4885OPRD1 1063/4885OPRK1 726/4885 |
| US-20210169886-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GAA, SNCA | OPRM1 805/4885OPRD1 1063/4885OPRK1 726/4885 |
| US-11400095-B2 | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | OPRM1 805/4885OPRD1 1063/4885OPRK1 726/4885 |
| US-10786508-B2 | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders | GBA1, GAA, SNCA | OPRM1 871/4885OPRD1 1278/4885OPRK1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.